PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Abstract Molecularly targeted cancer therapies substantially improve patient outcomes, although the durability of their effectiveness can be limited. Resistance to these therapies is often related to adaptive changes in the target oncoprotein which reduce binding affinity. The arsenal of targeted ca...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | Molecular Cancer |
| Online Access: | https://doi.org/10.1186/s12943-022-01707-5 |